Join our daily newsletter At The Bell to receive exclusive market insights
- Clinuvel Therapeutics has renewed its employment agreement with Managing Director Dr Philippe Wolgen for three years
- Dr Philippe has steered the company since its restructure in 2005
- He was instrumental in the $95 million capital raise for the funding of SCENESSE
- Clinuvel has ended the day up 4.15 per cent, trading for $27.10 per share
Clinuvel Therapeutics has renewed the employment agreement with life science executive and Managing Director Dr Philippe Wolgen for three years.
According to the Board of Directors, Dr Philippe has steered the company since its restructure in 2005 to its current successful position.
“The Board of Directors and larger investors are clear in their opinion that we want to retain Philippe and see him supported by a stable senior management team in order to continue the Company’s successful journey,” Chair, Stan McLiesh said.
“We believed that successful execution of our strategy should see continued growth in shareholder value. I am grateful to all who have contributed to finalise this positive outcome for the Company today,” Stan added.
Dr Philippe holds an MBA from Columbia University NY and the London Business School.
He is trained as a craniofacial surgeon and holds an MD from the University of Utrecht in the Netherlands.
He has held positions in private pharmaceutical companies in Europe, been Managing Director of two medical centres in the U.K. and Israel, and consulted medical device companies.
Dr Philippe has been instrumental in raising $95 million since 2006 for the funding of the current development program of SCENESSE.
Its SCENESSE product is designed to assist people who have erythropoietic protoporphyria: a condition which leaves skin hypersensitive to the sun causing pain or burning.
In light of this news Clinuvel has ended the day up 4.15 per cent with shares priced at $27.10 apiece.
